Regeneron Pharmaceuticals (REGN) closed at $923.34 on November 19, 2026, down 2.3% from the previous close, on volume of 665,841 shares (30-day average 863,809).
Data as of November 19, 2026.
19-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Seagull With Call Spread | 06-Nov-26750 P : 835 C : 880 C | 1,050 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
TipRanks (Thu, 19-Nov 8:06 AM ET)
Regeneron, Alnylam win FDA nod for myasthenia gravis therapy
Seeking Alpha News (Thu, 19-Nov 7:14 AM ET)
Globe Newswire (Thu, 19-Nov 7:00 AM ET)
Globe Newswire (Wed, 18-Nov 6:03 PM ET)
Regeneron Advances Early Blood-Disorder Study as REGN17235 Trial Recruits
TipRanks (Wed, 18-Nov 11:32 AM ET)
CytomX to receive $5M from Regeneron for cancer drug milestone
Seeking Alpha News (Tue, 17-Nov 9:02 PM ET)
Regeneron wins EU nod for alternative Libtayo regimen
Seeking Alpha News (Tue, 17-Nov 2:17 PM ET)
Globe Newswire (Tue, 17-Nov 7:00 AM ET)
Alnylam tops healthcare earnings surprise list, ahead of Regeneron and Eli Lilly
Seeking Alpha News (Tue, 17-Nov 6:08 AM ET)
SA Asks: What are the most attractive Big Pharma stocks right now?
Seeking Alpha News (Sun, 15-Nov 2:56 PM ET)
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.
As of November 19, 2026, REGN stock price declined to $923.34 with 665,841 million shares trading.
REGN has a beta of 0.01, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.00 to the broad based SPY ETF.
REGN has a market cap of $95.52 billion. This is considered a Large Cap stock.
Last quarter Regeneron Pharmaceuticals reported $5 billion in Revenue and $20.07 earnings per share. This beat revenue expectation by $556 million and exceeded earnings estimates by $4.32.
In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.
The top ETF exchange traded funds that REGN belongs to (by Net Assets): VOO, VTI, QQQ, IVV, SPY.
REGN has outperformed the market in the last year with a price return of +32.1% while the SPY ETF gained +9.6%. REGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.8% and +2.3%, respectively, while the SPY returned -6.5% and -6.6%, respectively.
REGN support price is $924.47 and resistance is $966.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.